Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance) Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C10403
Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502 Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10502
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502
Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502 Attar, Eyal C. , Johnson, Jeffrey L. , Amrein, Philip C. ... - - J. Clin. Oncol. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502
Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720) Baer, M. R. , George, S. L. , Sanford, B. L. , Bothun, S. M. ... - - Blood - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720
Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies Baer, M. R. , George, S. L. , Sanford, B. L. , Stone, R. M. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9720
Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia Baer, M. R. , Kolitz, J. E. , George, S. L. , Caligiuri, M. A. ... - - Ann Hematol - 2008 Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-19808
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 Baer, MR , George, SL , Sanford, BL , Mrózek, K , Kolitz, JE ... - - Leukemia - 2011 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9720
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study Blum, W. , Donohue, K. , Marcucci, G. , Deangelo, D. J. , Uy, G. L. ... - ASH - Blood - 2010 Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-10503
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503) Blum, William , Sanford, Ben L. , Klisovic, Rebecca ... - - Leukemia - 2017 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance) Byrd, John C. , Ruppert, Amy S. , Heerema, Nyla A. ... - - Blood Adv - 2018 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10404
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Byrd, John C , Peterson, Bercedis L , Rai, Kanti R , Hurd, David ... - - Leuk. Lymphoma - 2009 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19901
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (Alliance) clinical trials Castillo, Jorge J. , Mulkey, Flora , Geyer, Susan ... - - Am. J. Hematol. - 2016 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - C9621 , C9710 , CALGB-10503 , CALGB-19808
Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies Castillo, Jorge J. , Mulkey, Flora , Geyer, Susan ... - - Blood - 2013 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-9621 , CALGB-9710 , CALGB-10503 , CALGB-19808
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801 DeAngelo, Daniel J. , Yu, Daohai , Johnson, Jeffrey L. ... - - Blood - 2007 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19801
Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - N1087
Akt Inhibitor MK2206 Selectively Targets CLL B-cell Receptor Induced Cytokines, Mobilizes Lymphocytes and Synergizes with Bendamustine to Induce CLL Apoptosis Ding, Wei , Shanafelt, Tait D. , Lesnick, Connie E. ... - - Br. J. Haematol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - N1087
The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance) Ding, Wei , Shanafelt, Tait D. , Zent, Clive S. , Leis, Jose F. ... - - Blood - 2013 Abstract - Primary Endpoint - Primary Analysis - Leukemia - N1087
Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603) Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study Döhner, Konstanze , Thiede, Christian , Larson, Richard A. ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Aged 60–70 Years with Acute Myeloid Leukemia in First Remission Farag, Sherif S. , Maharry, Kati , Zhang, Mei-Jie , Pérez, Waleska S. ... - - Biol. Blood Marrow Transplant. - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-9720 , CALGB-10201
Dose intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup study C9710 Feusner, J. , Gregory, J. , Moser, B. K. , Hars, V. , Powell, B. L. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C9710
Treatment of Myelodysplastic Syndrome with Two Schedules and Doses of Oral Topotecan: A Randomized Phase II Trial by the Cancer and Leukemia Group B (CALGB 19803) Grinblatt, David L. , Yu, Daohai , Hars, Vera , Vardiman, James W. ... - - Cancer - 2009 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19803
A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance) Gupta, Pankaj , Mulkey, Flora , Hasserjian, Robert P. ... - - Invest New Drugs - 2013 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10105
Optimal Two-Stage Dynamic Treatment Regimes from a Classification Perspective with Censored Survival Data Hager, Rebecca , Tsiatis, Anastasios A. ... - - Biometrics - 2018 Manuscript - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - C9710
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101 Jones, J. A. , Ruppert, A. S. , Zhao, W. , Lin, T. S. , Rai, K. ... - - Leuk. Lymphoma - 2013 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-19901 , CALGB-10101
Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials Jones, J. A. , Stark, A. , Zhao, W. , Lin, T. S. , Rai, K. R. ... - - Blood - 2011 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-10101 , CALGB-19901
Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808 Kolitz, J. E. , Hars, V. , Deangelo, D. J. , Allen, S. L. ... - - Blood - 2007 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-19808 , CALGB-8461 , CALGB-9665
Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission Kolitz, Jonathan E. , George, Stephen L. , Benson, Don M. ... - - Cancer - 2014 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Leukemia - CALGB-19808
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 Kolitz, Jonathan E. , George, Stephen L. , Marcucci, Guido ... - - Blood - 2010 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19808 , CALGB-8461
Outcome for Pediatric Acute Promyelocytic Leukemia Patients at Children’s Oncology Group Sites on the Leukemia Intergroup Study CALGB 9710 (Alliance) Kutny, Matthew A. , Geyer, Susan , Laumann, Kristina M ... - - Pediatr Blood Cancer - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-9710
A Comparison of Outcomes between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance) Kutny, Matthew A. , Geyer, Susan , Laumann, Kristina M ... - ASH - Blood - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - C9710
Effect of young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance) Kutny, Matthew A. , Gregory, John , Geyer, Susan , Laumann, Kristina ... - ASH - Blood - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - C9710
What Determines the Outcome for Adolescents and Young Adults With Acute Lymphoblastic Leukemia? Larson, R. A. ... - - Ann Hematol - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - C8811 , C9331 , CALGB-19802 , CALGB-8461
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations Larson, Richard A. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10603
Application of multi-state models in cancer clinical trials Le-Rademacher, Jennifer G , Peterson, Ryan A , Therneau, Terry M ... - - Clin Trials - 2018 Manuscript - No-Endpoint Endpoint - Other Analysis - Leukemia - A151732 , CALGB-10603
Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study Li, Zejuan , Herold, Tobias , He, Chunjiang , Valk, Peter J.M. ... - - J. Clin. Oncol - 2013 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - CALGB-19808 , CALGB-9222 , CALGB-9621 , CALGB-9710 , CALGB-9720
Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101 Lin, T. S. , Donohue, K. A. , Byrd, J. C. , Lucas, M. S. , Hoke, E. ... - - Blood - 2009 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10101
Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101 Lin, T. S. , Donohue, K. A. , Lucas, M. S. , Byrd, J. C. ... - - Blood - 2007 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10101
Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101 Lin, Thomas S. , Donohue, Kathleen A. , Byrd, John C. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10101
Auto-SCT for AML in second remission: CALGB study 9620. Linker, C A , Owzar, K , Powell, B , Hurd, D , Damon, L E , Archer, L E ... - - Bone Marrow Transplant. - 2009 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9620
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era Mantha, Simon , Goldman, Debra A. , Devlin, Sean M. , Lee, Ju-Whei ... - - Blood - 2017 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-9710
A phase III randomized trial of intensive induction and consolidation chemotherapy +/- oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old Marcucci, G. , Moser, B. K. , Blum, W. G. , Stock, W. , Wetzler, M. ... - ASCO - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10201
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801 Marcucci, Guido , Geyer, Susan , Laumann, Kristina , Zhao, Weiqiang ... - - Blood Adv - 2020 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10801 , CALGB-20202
Adding the KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB study 10801 (Alliance) Marcucci, Guido , Geyer, Susan , Zhao, John , Caroll, Andrew J ... - ASH - Blood - 2014 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10801
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222 Moore, Joseph O. , George, Stephen L. , Dodge, Richard K. ... - - Blood - 2005 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9222
Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901) Morrison, V. A. , Peterson, B. L. , Rai, K. R. , Byrd, J. C. ... - ASH - Blood - 2007 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - C9011 , CALGB-19901 , CALGB-9712
Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301 Orlowski, R. Z. , Peterson, B. L. , Sanford, B. , Chanan-Khan, A. A. ... - ASH - ASH Annual Meeting Abstracts - 2006 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10301
Concomitant use of midostaurin with Strong CYP3A4 inhibitors: An analysis from the CALGB 10603/RATIFY Trial (Alliance) Ouatas, Taoufik , Duval, Vincent , Sinclair, Karen ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype Poiré, Xavier , Moser, Barry K. , Gallagher, Robert E. ... - - Leuk. Lymphoma - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-9710
Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710 Powell, B. L. , Moser, B. K. , Stock, W. , Gallagher, R. E. ... - - Blood - 2011 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C9710
Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. Powell, B. L. , Moser, B. , Stock, W. , Gallagher, R. E. , Willman, C. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Leukemia - C9710
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710 Powell, Bayard L. , Moser, Barry , Stock, Wendy ... - - Blood - 2010 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - C9710
Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Rai, K. R. , Peterson, B. L. , Appelbaum, F. R. , Tallman, M. S. ... - ASH - Blood - 2009 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Leukemia - C9011
Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002 Rizzieri, D. A. , Johnson, J. L. , Byrd, J. C. , Lozanski, G. ... - - Blood - 2010 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10002
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002 Rizzieri, David A. , Johnson, Jeffrey L. , Byrd, John C. ... - - Br. J. Haematol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10002
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance) Roboz, Gail J. , Mandrekar, Sumithra J. , Desai, Pinkal ... - - Blood Adv - 2018 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-11002
Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia Ruppert, A S , Yin, J , Davidian, M , Tsiatis, A A , Byrd, J C ... - - Ann. Oncol - 2019 Manuscript - No-Endpoint Endpoint - Other Analysis - Leukemia - A041202
A Genetic Risk-Stratified, Phase II Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated Chronic Lymphocytic Leukemia (CLL): Final Results of Cancer and Leukemia Group B (CALGB) 10404 (Alliance) Ruppert, Amy S. , Byrd, John C. , Heerema, Nyla A. , Smith, Mitchell ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10404
Prognostic impact of insertion site in acute myeloid leukemia with FLT3 internal tandem duplication: results from the RATIFY study (Alliance) Rücker, Frank G. , Du, Ling , Blätte, Tamara J. , Benner, Axel ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic Lymphocytic Leukemia (CLL) Shanafelt, Tait , Zent, Clive , Byrd, John , Erlichman, Charles ... - - Leuk. Lymphoma - 2010 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - N048F , N0683
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. Silverman, Lewis R , Demakos, Erin P , Peterson, Bercedis L ... - - J. Clin. Oncol. - 2002 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9221
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Solh, Melhem , Rai, Kanti R , Peterson, Bercedis L ... - - Leuk. Lymphoma - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-9011
Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102) Stock, W. , Sanford, B. , Lozanski, G. , Vij, R. , Byrd, J. C. ... - ASH - Blood - 2009 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10102
An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia Stock, Wendy , Diouf, Barthelemy , Crews, Kristine R. , Pei, Deqing ... - - Clin. Pharmacol. Ther. - 2017 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - CALGB-10102 , CALGB-10403 , CALGB-19802 , CALGB-9862
Dose Intensification of Daunorubicin and Cytarabine during Treatment of Adult Acute Lymphoblastic Leukemia: Results of Cancer and Leukemia Group B Study 19802 Stock, Wendy , Johnson, Jeffrey L. , Stone, Richard M. ... - - Cancer - 2013 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19802
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies Stock, Wendy , La, Mei , Sanford, Ben , Bloomfield, Clara D. ... - - Blood - 2008 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - CALGB-8811 , CALGB-9331 , CALGB-19802 , CALGB-8461 , CALGB-9111 , CALGB-9511
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 Stock, Wendy , Luger, Selina M. , Advani, Anjali S. , Yin, Jun ... - - Blood - 2019 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10403
Favorable outcomes for adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early results of US Intergroup trial CALGB 10403 (Alliance) Stock, Wendy , Luger, Selina , Advani, Anjali , Geyer, Susan ... - ASH - Blood - 2014 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10403
CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML Stone, R. M. , Dohner, H. , Ehninger, G. , Villeneuve, M. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Preliminary Analysis - Leukemia - CALGB-10603
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation Stone, Richard M. , Mandrekar, Sumithra J. , Sanford, Ben L. ... - - N. Engl. J. Med. - 2017 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10603
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Midostaurin v Placebo plus Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation and Maintenance Therapy in Newly Diagnosed Acute Myeloid Leukemia ( AML) Patients ( pts) age 18-60 with FLT3 mutations: An International Prospective Randomized Placebo-Controlled Double-Blind Trial (CALGB 10603 [Alliance]) Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2015 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10603
High Dose Cytarabine plus Gemtuzumab Ozogamicin for Patients with Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902 Stone, Richard M. , Moser, Barry , Sanford, Ben , Schulman, Philip ... - - Leuk Res - 2011 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19902
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Stone, Richard M , Donohue, Kathleen A , Stock, Wendy , Hars, Vera ... - - Cancer Chemother. Pharmacol. - 2009 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19804
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group Tallman, M. S. , Kim, H. T. , Montesinos, P. , Appelbaum, F. R. ... - - Blood - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - INT-0129
FLT3 mutation assay laboratory cross validation: results from the CALGB 10603/RATIFY(Alliance) trial in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) Thiede, Christian , Prior, Thomas , Coco, Francesco Lo ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Allogeneic Hematopoietic Cell Transplantation (HCT) vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG and CIBMTR Study Ustun, Celalettin , Le-Rademacher, Jennifer G , Wang, Hailin ... - ASH - Blood - 2018 Abstract - Primary Endpoint - Primary Analysis - Leukemia - A151509 , CALGB-100103
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001 Uy, Geoffrey L. , Mandrekar, Sumithra J. , Laumann, Kristina ... - - Blood Adv - 2017 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-11001
Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults With FLT3-ITD Mutated AML (Alliance C11001). Uy, Geoffrey L. , Mandrekar, Sumithra , Laumann, Kristina ... - ASH - Blood - 2015 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-11001
Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001) Uy, Geoffrey L. , Sanford, Ben , Marcucci, Guido , Zhao, Weiqiang ... - ASH - Blood - 2013 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-11001
Alliance A041701 - A randomized phase 2/3 study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute myeloid leukemia receiving intensive induction chemotherapy Uy, Geoffrey L. , Yin, Vivien , Klepin, Heidi , Dinner, Shira ... - ASH - - 2019 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Leukemia - A041701
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission Vasu, Sumithira , Kohlschmidt, Jessica , Mrózek, Krzysztof ... - - Blood Adv - 2018 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - C8221 , C8461 , C8525 , C8721 , C8821 , C9022 , C9720 , CALGB-19808 , CALGB-8923 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study Voorhees, Peter M. , Orlowski, Robert Z. , Mulkey, Flora ... - - Br. J. Haematol. - 2015 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10301
RATIFY: Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy (Alliance) Voso, Maria Teresa , Larson, Richard A. , Prior, Thomas W ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Ratify (Alliance 10603): Prognostic Impact of FLT3 Tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin Plus Standard Chemotherapy Voso, Maria Teresa , Larson, Richard A. , Prior, Thomas W ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001 Wetzler, M. , Stock, W. , Donohue, K. A. , Owzar, K. , Sher, D. A. ... - - Blood - 2007 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10001 , CALGB-8461 , CALGB-9665 , CALGB-9862
Imatinib and Autologous Stem Cell Transplantation for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) – CALGB study 10001 Wetzler, M. , Stock, W. , Linker, C. ... - - Ann Hematol - 2008 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10001
Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance) Wetzler, M. , Watson, D. , Stock, W. , Owzar, K. , Koval, G. , Hoke, E. ... - - Blood - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10001
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107 Wetzler, Meir , Donohue, Kathleen A. , Odenike, Olatoyosi M. ... - - Leuk. Lymphoma - 2008 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10107
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance) Wetzler, Meir , Watson, Dorothy , Stock, Wendy , Koval, Gregory ... - - Haematologica - 2014 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10001
A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance) Wieduwilt, Matthew J. , Yin, Jun , Wetzler, Meir , Uy, Geoff ... - ASH - Blood - 2016 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10701
A phase II study of dasatinib and dexamethasone as primary therapy followed by transplantation for adults with newly diagnosed PH/BCR-ABL1-positive acute lymphoblastic leukemia: Final results of Alliance/CALGB study 10701 Wieduwilt, Matthew J. , Yin, Jun , Wetzler, Meir , Uy, Geoff ... - ASH - Blood - 2018 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10701
Outcome of Adolescents and Young Adults with Acute Myeloid Leukemia Treated on COG Trials Compared to CALGB and SWOG Trials Woods, William G. , Franklin, Anna R.K. , Alonzo, Todd A. ... - - Cancer - 2013 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - CALGB-8525 , CALGB-9022 , CALGB-9222 , CALGB-9621 , CALGB-19808 , CALGB-8461
Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies Woyach, J. A. , Ruppert, A. S. , Peterson, B. , Rai, K. R. ... - - Blood - 2011 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - C9011 , CALGB-10101 , CALGB-9712
Treatment with fludarabine and rituximab produces extended remissions and survival in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: Long-term follow up of CALGB study 9712 Woyach, J. , Heerema, N. A. , Stark, A. , Peterson, B. L. ... - - Blood - 2009 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9712
Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712 Woyach, Jennifer A. , Ruppert, Amy S. , Heerema, Nyla A. ... - - J Clin Oncol - 2011 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Leukemia - CALGB-9712
Ibrutinib alone or in combination with rituximab produces superior progression free survival compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia: Results of Alliance A041202 Woyach, Jennifer A. , Ruppert, Amy S. , Heerema, Nyla ... - ASH - Blood - 2018 Abstract - Primary Endpoint - Primary Analysis - Leukemia - A041202
Impact of Age on Outcomes After Initial Therapy With Chemotherapy and Different Chemoimmunotherapy Regimens in Patients With Chronic Lymphocytic Leukemia: Results of Sequential Cancer and Leukemia Group B Studies Woyach, Jennifer A. , Ruppert, Amy S. , Rai, Kanti , Lin, Thomas S. ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leukemia - C9011 , CALGB-9712 , CALGB-19901 , CALGB-10101
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. Woyach, Jennifer A , Ruppert, Amy S , Heerema, Nyla A ... - - N. Engl. J. Med. - 2018 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - A041202
Event-free survival as a surrogate endpoint for overall survival in previously untreated acute myeloid leukemia: An individual patient-level analysis of multiple randomized trials (Alliance A151614) Yin, Jun , LaPlant, Betsy , Storrick, Elizabeth , Uy, Geoffrey L. ... - ASH - Blood - 2018 Abstract - Primary Endpoint - Comprehensive Analysis - Leukemia - A151614 , CALGB-10201 , E1900 , CALGB-10603 , S0106
Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614) Yin, Jun , LaPlant, Betsy , Uy, Geoffrey L. , Marcucci, Guido ... - - Blood Adv - 2019 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - A151614 , CALGB-10201 , CALGB-10503 , CALGB-10603 , CALGB-10801 , CALGB-11001
Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia Yin, Jun , Laplant, Betsy R. , Uy, Geoffrey L. , Marcucci, Guido ... - ASH - JAMA Oncol - 2016 Abstract - Primary Endpoint - Primary Analysis - Leukemia - A151614 , CALGB-10201 , CALGB-10503 , CALGB-10603 , CALGB-10801 , CALGB-11001
